Pathogenetic role of visceral adipose tissue in the development of non-alcoholic fatty liver disease in patients with metabolic syndrome
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 3
Abstract
Objective — to study the nature of changes in carbohydrate and lipid metabolism, depending on the distribution and activity of visceral adipose tissue (VAT), and the degree of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) against the background of a metabolic syndrome (MS). Materials and methods. Were examined 62 patients with NAFLD: 26 men (40 %) and 36 women (60 %). The mean age of patients was 57.3 ± 9.2 years. The control group consisted of 30 healthy donors of the same age group of males and females. All patients were assessed the parameters of an objective examination and laboratory and instrumental examination in accordance with the current order MOH № 826 from 06.11.2014. In addition to the standard survey, the body composition of patients was monitored, and the visceral adiposity index (VAI) was calculated by the method of Amato MC (2010) to determine visceral adipose tissue dysfunction (VAT). Statistical processing of data was carried out using the SPSS 17.0 software package. Results. In patients with NAFLD, elevated insulin levels 29.23 ± 5.26 μS/ml were established in comparison with control group 6.83 ± 2.08 μS/ml and a significant increase in the HOMA index to 8.93 ± 3.01 μmol fructose/1 g Nv (p < 0.05). The maximum levels of insulin and the HOMA-IR index were found in patients with high IVO that exceeded 5μm. unit. Concentrations of total cholesterol (CH), triglycerides (TG), low density lipoprotein (LDL) in patients with NAFLD were also significantly higher than those in the control group (p < 0.05). The maximal TG level 2.87 ± 0.14 mmol was observed in patients with high IVO (p < 0.05). In addition to the changes in carbohydrate and lipid metabolism rates, with the degree of fusion of IVO, the steatosis rates (p < 0.05) also increased. Conclusions. The obtained data evidence about the dependence of the depth of the carbohydrate and lipid metabolism violations on the activity. In patients with NAFLD against the background of MS, index HOMA-IR and CH, TG, LDL and degree of steatosis significantly increased with the growth of IVO (p < 0.05), which makes it possible to consider IVO as a significant additional prognostic criterion for the risk of development of not only metabolic disorders, but also as a risk factor for the progression of fibroblastic processes.
Authors and Affiliations
G. D. Fadieienko, I. E. Kushnir, V. M. Chernova, Т. А. Solomentseva, Ya. V. Nikiforova
Keywords
Related Articles
- EP ID EP298565
- DOI 10.30978/MG-2018-3-29
- Views 136
- Downloads 0
Idiopathic non-cirrhotic portal hypertension and Budd — Chiari syndrome: focus on the problem
The idiopathic non-cytolytic portal hypertension and Budd — Chiari syndrome refer to orphan diseases, however last time the incidence of these liver diseases is being increased recently, especially among young people. Th...
The use of probiotics for the prevention and correction of the antibiotic resistance
The antibiotic resistance interferes with the effective prevention and treatment of a number of infections, caused by bacteria, fungi etc., and its quantity is constantly increased. Without effective antibiotics, the eff...
State of the hepatobiliary system in boys with hypoandrogenism
Objective — to study the state of hepatobiliary system in boys/youths with delayed puberty. Materials and methods. The study involved 37 boys and youths with hypoandrogenism, aged 13 — 18 years, who were examined in the...
Functional dyspepsia and immune dysfunction: modern concepts of pathogenetic mechanisms of their development
The review presents the main modern opinions on the immunological factors of functional dyspepsia development and data on its micromorphological basis. The immune dysfunction is considered as an important factor in the p...
Clinical Practice Guidelines of European Association for the Study of the Liver (EASL) on nutrition in chronic liver disease. Part 3
_